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Abstract
Background: Stem cell expansion and differentiation is the foundation of emerging cell therapy technologies. The potential
applications of human neural progenitor cells (hNPCs) are wide ranging, but a normal cytogenetic profile is important to
avoid the risk of tumor formation in clinical trials. FDA approved clinical trials are being planned and conducted for hNPC
transplantation into the brain or spinal cord for various neurodegenerative disorders. Although human embryonic stem cells
(hESCs) are known to show recurrent chromosomal abnormalities involving 12 and 17, no studies have revealed
chromosomal abnormalities in cultured hNPCs. Therefore, we investigated frequently occurring chromosomal abnormalities
in 21 independent fetal-derived hNPC lines and the possible mechanisms triggering such aberrations.
Methods and Findings: While most hNPC lines were karyotypically normal, G-band karyotyping and fluorescent in situ
hybridization (FISH) analyses revealed the emergence of trisomy 7 (hNPC
+7) and trisomy 19 (hNPC
+19), in 24% and 5% of the
lines, respectively. Once detected, subsequent passaging revealed emerging dominance of trisomy hNPCs. DNA microarray
and immunoblotting analyses demonstrate epidermal growth factor receptor (EGFR) overexpression in hNPC
+7 and hNPC
+19
cells. We observed greater levels of telomerase (hTERT), increased proliferation (Ki67), survival (TUNEL), and neurogenesis
(bIII-tubulin) in hNPC
+7 and hNPC
+19, using respective immunocytochemical markers. However, the trisomy lines underwent
replicative senescence after 50–60 population doublings and never showed neoplastic changes. Although hNPC
+7 and
hNPC
+19 survived better after xenotransplantation into the rat striatum, they did not form malignant tumors. Finally, EGF
deprivation triggered a selection of trisomy 7 cells in a diploid hNPC line.
Conclusions: We report that hNPCs are susceptible to accumulation of chromosome 7 and 19 trisomy in long-term cell
culture. These results suggest that micro-environmental cues are powerful factors in the selection of specific hNPC
aneuploidies, with trisomy of chromosome 7 being the most common. Given that a number of stem cell based clinical trials
are being conducted or planned in USA and a recent report in PLoS Medicine showing the dangers of grafting an inordinate
number of cells, these data substantiate the need for careful cytogenetic evaluation of hNPCs (fetal or hESC-derived) before
their use in clinical or basic science applications.
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Introduction
Stem cell expansion and differentiation is the foundation of
emerging cell therapy technologies. The most primitive embryonic
stem cells (ESCs), derived from the developing blastocyst, have
diploid karyotypes that can remain stable after many passages in
vitro [1,2]. However, there have been many reports that these cells
may acquire specific recurrent chromosomal abnormalities after
prolonged culture. These include aneuploidy with gain of
chromosomes (trisomy) 12, 17, and X in human ESCs [2–5]
and trisomy 8 and 11 in mouse ESCs [6,7]. These abnormalities
lead to differential growth rates [2–4], thus lessening the
reproducibility and reliability. Furthermore, use of hESCs for
clinical trials must ensure that they maintain a normal karyotype
to avoid possible malignant tumor formation after transplantation.
More restricted human neural progenitor cells (hNPCs) can be
isolated from different regions of the developing human brain,
expanded in culture and then differentiated into neurons and
astrocytes [8–12]. There have been many reports showing that
hNPCs can be used in vitro to study the mechanisms of
neurogenesis and also transplanted into the developing or adult
rodent brain [8–12]. Upon grafting, the cells have the ability to
integrate, migrate and develop into both neurons and astrocytes
[13–15] without any evidence of teratoma formation, a common
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7630problem for studies using hESCs. As such they represent an
interesting source of tissue for cell therapy, either alone or
following modification to release potent growth factors [16,17].
Compared to hESCs, most hNPCs do not express high levels of
telomerase and show senescence patterns after between 50 and 70
population doublings [18,19]. There are suggestions that telencephalic
proliferative regions of the mammalian brain, including the embryonic
cerebral cortex and postnatal SVZ may contain a population of
aneuploid cells [20–22]. Nevertheless, there have been no previous
reports of recurrent chromosome changes in cultures of hNPCs. In the
current study, after karyotyping 21 hNPC lines in preparation for
generating a clinically viable cell bank, we discovered for the first time
that trisomy 7 occurs in five independently derived hNPC lines and
trisomy 19 was observed in only one hNPC line. Once established, the
lines with trisomy have a selective advantage. One of the most
susceptible lines showed high levels of endogenous telomerase
expression in the trisomy hNPCs, and stress through epidermal growth
factor (EGF) deprivation potentially triggered selection and enrichment
of trisomy 7 cells in an otherwise normal line.
Results
Gain of chromosome 7 or 19 can be found in some hNPC
lines
Human NPCs isolated from fetal brain tissue between ten to
fifteen weeks of post-conception were maintained in neural
expansion medium consisting of epidermal growth factor (EGF)
and fibroblast growth factor-2 (FGF-2) and then switched to EGF
and leukemia inhibitory factor (LIF) as described in detail
previously [19,23]. Twenty-one independent lines of hNPCs
derived from cortex or ventral mesencephalon samples, were
cultured, karyotyped, and characterized in our laboratory
(Table 1). While the majority of cultures were karyotypically
normal diploid population (hNPC
dip in Fig. 1A and B), some sub-
cultures of five hNPC lines (G001, G002, G010, M031, and
M046) displayed a complete trisomy of chromosome 7 (hNPC
+7)
after 9–15 weeks in culture (24% of the 21 lines tested) confirmed
using both G-banding and FISH (Table 1, Figure 1C and D,
respectively). Furthermore, in the M031 line a trisomy of
chromosome 19 (hNPC
+19) appeared after 15–25 weeks in culture
(5% of the 21 lines tested) (Table 1, Figure 1E and F). Two of the
hNPC lines were obtained from fetal brain tissue of Down’s
syndrome patients that present with a trisomy of chromosome 21,
however, these lines did not show trisomy 7 or 19. The only other
unbalanced karyotype was observed in one line with an intercalary
deletion of chromosome 13, in band q21 (Table 1), suggesting a
unique sensitivity of chromosomes 7 and 19 to trisomy.
Once detected in a sub culture, the frequency of hNPC
+7 or
hNPC
+19 occurring cells increased over subsequent passages and
entirely predominated within ten to fifteen weeks of first detection
suggesting a selective advantage of the trisomy cells (Table S1).
Although these trisomies were seen in some thawed cell lines, other
lines derived from the parental M031
dip line maintained their
normal karyotype for over fifty weeks in culture, after which they
senesced (data not shown). Thus, the process of trisomy formation
between different hNPC lines or selection of rare trisomy cells within
the culture appears stochastic. Subsequent studies in the current
reportwereperformed withthekaryotypicalllynormaldiploidM031
line (M031
dip) and its trisomy derivatives, M031
+7 and M031
+19.
Trisomy hNPCs display faster growth kinetics and a
proliferative advantage
In order to determine the effect of these trisomies on cell growth




+19 sub cultures at passage 25 from the M031 cell line.
Based on morphological appearance, the trisomy cultures grown
as neurospheres did not differ from normal diploid line (Figure
S1A). Both showed normal numbers of filopodia at their outer
edges and could be efficiently expanded, dissociated and plated.
Subsequently, volumetric measurements of single spheres were
used to assess the growth rates of the three lines. Neurospheres
from M031
+7 and M031
+19 cultured under standard conditions
had ,100% and 60% greater increase in neurosphere volume,
respectively, than the diploid line (Figure S1A and S1B).
To determine whether the faster growth kinetics observed in the
cultures with trisomy was due to increased cell proliferation or
inhibition of cell death, we performed both proliferation and cell
death assays. The Ki67 protein is a well-known cellular marker
strictly associated with cell proliferation. Neurospheres from the
three lines were dissociated as single cells and plated down on glass
coverslips for 2 h prior to fixation and staining with Ki67
(Figure 2A–C). There were significantly more Ki67 positive cells
in both M031
+7 (21%) and M031
+19 (22%) compared to the
M031
dip control parental line (10%) (Figure 2D).
We next visualized cells exhibiting typical morphological
features of apoptosis such as DNA fragmentation, chromatin
condensation and pyknotic nuclei using TUNEL staining
(Figure 2E–G). This showed a decreased number of TUNEL
positive cells, (13% and 22% in M031
+7 and M031
+19,
respectively) compared to the M031
dip line (30%) (Figure 2H).
These results suggest that both increased proliferation and
decreased cell death contribute to the increased survival and
growth of the hNPC
+7 and hNPC
+19 lines.
Limited replicative capacity is a consistent characteristic of
somatic cells during in vitro passaging, ultimately resulting in
senescence mainly associated with telomere erosion [24]. Human
telomerase reverse transcriptase (hTERT) expression can inhibit
telomere erosion and has powerful effects including the induction
of senescence-associated genes [25–27]. To determine whether
telomerase was altered in the aneuploid hNPCs to explain
extended growth, we quantified telomerase expression by
immunocytochemistry (Figure 2I–K). There was a significant
increase in the number of hTERT positive cells in M031
+7 and
M031
+19 hNPCs after acute platedown to ,49% and 48%,
respectively, when compared to M031
dip cells (,31%) (Figure 2L).
However, even with higher telomerase expression the trisomy
hNPCs entered a senescence phase between 50 and 70 weeks in
vitro (data not shown). These data suggest that while increases in
hTERT may enhance proliferation and survival rates, they may
not delay eventual senescence of the cells as we have shown
previously for diploid hNPCs [19].
Trisomy hNPCs demonstrate enhanced survival and
neurogenesis following differentiation
To determine whether the trisomy hNPCs have a survival
advantage during differentiation, the percent of Ki67 and TUNEL
positive cells were compared with M031
dip controls at similar
passages. Interestingly, the survival of trisomy hNPCs (22–30%
Ki67+ and 18–26% TUNEL+) upon differentiation was signifi-
cantly increased when compared to M031
dip controls (12% Ki67+
and 24–38% TUNEL+) at similar passages (Figure S2).
Next, we assessed the rate of neurogenesis by dissociating
neurospheres and plating them on laminin coated coverslips in
mitogen-free media and establishing the number of differentiating
neurons and astrocytes. The M031
+7 and M031
+19 lines generated
significantly more bIII-tubulin positive neurons compared to
M031
dip controls following one day, one week and two weeks of
differentiation (Figure S3). In addition, GFAP positive astrocytes
Trisomies in Neural Stem Cells




dip controls (70–90%). Thus, the trisomies led
to increased survival and neurogenesis with decreased gliogensis
following differentiation of hNPCs.
EGFR family is over-expressed in trisomy hNPCs
In order to examine the molecular mechanisms underlying the
differences between diploid and trisomy hNPCs we compared the
expression of signal transduction genes using Affymetrix GeneChip
DNA microarray analysis comparison of M031
dip and M031
+7
lines. This experimental design allowed us to reduce the statistical
impact of line to line variations. Of the total genome, microarray
comparison revealed 1,154 genes up-regulated more than 1.5 fold
and 462 genes down regulated. Only 105 genes were up-regulated
and 16 were down-regulated more than 1.5 fold of the total 1,150
genes on chromosome 7. Interestingly, the expression of the
epidermal growth factor receptor (EGFR) gene increased 1.7 fold
(Table S2). To confirm the changes in EGFR expression, Western
blot analysis performed on cell lysates from M031
dip, +7, and +19 lines
demonstrated that M031
+7 and M031
+19 lines over-express EGF
receptor family proteins, including human epidermal growth factor
receptor 2 (Her-2/neu/ErbB2), resulting in increased activation of
phosphorylated EGFR (Tyr992) (Fig. 3A). Densitometric quantifi-
cation of the protein bands supports the GeneChip EGFR mRNA
over-expression data (Figure 3B).
Exogenous EGF depletion may favor survival of trisomy
hNPCs in vitro
To address the possibility that M031
+7 cells may manifest
EGF-independent growth characteristics, we omitted EGF from
Table 1. Abnormal findings in cytogenetic and FISH analysis performed on twenty-one independently derived hNPC lines.
No. hNPC lines Passage Karyotype * Abnormal (%) * +7( % ){ +19 (%) { +7 and +19 (%) {
1 G001 VM p29 NP NP Normal NP NP
2 G002 VM p29 NP NP Normal NP NP
3 G001 CTX " p10 – p15 # 47,XY,+7 16 – 100 10 – 70 NP NP
4 G002 CTX " p9 – p18 # 47,XY,+7 10 – 100 16 – 100 NP NP
5 G007 CTX p3 – p4 # NP NP Normal Normal Normal
6 G010 CTX D p4 – p20 # 46, XY NP Normal Normal Normal
G010 CTX D " p23 – p25 # NP NP 2 – 3.4% Normal Normal
7 G016 CTX p4 – p20 # NP NP Normal Normal Normal
8 K050 CTX p25 Normal NP NP NP NP
9 K055 CTX p20 Normal NP NP NP NP
10 K057 CTX p38 Normal NP NP NP NP
11 M006 CTX p3 – 21 # Normal NP NP NP NP
12 M007 CTX p3 Normal NP NP NP NP
13 M024 CTX p12 Normal NP NP NP NP
14 M031 CTX D p4 – p29 # Normal NP Normal Normal Normal
M031 CTX
+7D " p14 – p38 # 47,XY,+7 5 – 100 3 – 99 Normal Normal
M031 CTX
+19 D " p19 – p38 # 47,XY,+19 5 – 95 Normal 3 –55 Normal
M031 CTX D " p29 47,XY,+19 40 NP NP NP
M031 CTX D " p29 48,XY,+7, +1 9 5 N PN PN P
M031 CTX D " p38 NP NP 93 Normal 5
M031 CTX D " p38 NP NP 34 3 0
15 M038 CTX p20 NP NP Normal Normal Normal
16 M046 CTX D p4 – 21 # Normal NP NP NP NP
M046 CTX D " p13 NP NP 2 Normal Normal
17 M067 CTX p4 Normal NP NP NP NP
18 M099 mid CTX p4 NP NP Normal Normal Normal
19 M099 OCCCTX p4 NP NP Normal Normal Normal
20 B001 CTX
‘ p2 47,XY,+21 99 NP NP NP
21 B003 CTX
‘ p3 47,XX,+21 99 NP NP NP
*- Cytogenetic G-band karyotyping results with the percent abnormal based on analysis of 20 metaphase cells, { - FISH analysis results showing the percent of cells
displaying either trisomy 7 (+7) or trisomy 19 (+19) based on counting signals in at least 200 nuclei. Normal results from a cytogenetic or FISH study are stated. Tests that
were not performed are represented by ‘‘NP’’ in the relevant column. Whenever an aberration was detected, the absolute number or the range of per cent abnormal
cells from passage to passage is indicated.
D - The results for multiple passages from one line or its derivatives tested are listed in different rows.
# - The passage range in a row indicates testing of the line or its derivative at different passages.
" - Five out of 21 lines were identified as susceptible to +7 and only M031 CTX was identified with +19.
‘- B001 and B003 CTX lines were obtained from Down’s syndrome patients that present with a trisomy 21 (+21).
doi:10.1371/journal.pone.0007630.t001
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Following 12-day EGF withdrawal, M031
+7 showed a 2-fold
increase in EGF-independentg r o w t hw h e nc o m p a r e dt o
M031
dip as revealed by an increase of 9% in Ki67 positive cells
and a 10% decrease in TUNEL positive cells (Figure 4A and B),
which may likely be a result of EGF receptor over-expression in
the M031
+7 cells.
Subsequently, we investigated whether EGF deprivation may
lead to the emergence of trisomy 7 or other associated
abnormalities [28,29]. Two cortical hNPC lines, G010 and
G016, were used. At early passages these cells were karyotypically
normal and had never previously been cryo-preserved (Figure 4C).
EGF was removed from the media for four weeks and then added
back to both cultures at which time they were grown for an
additional two weeks and processed for FISH analysis. Interest-
ingly, the G016 line presented an extra copy of a chromosome 7
(7% of the cell population) (Figure 4C), when compared to a sister
culture maintained in EGF throughout the experiment. However,
the G010 line was karyotypically normal before and after the
exogenous EGF depletion (Figure 4C). This data shows that in one
hNPC line, stress through removal of exogenous EGF either
triggers a trisomy 7 or selects for rare trisomy 7 cell(s) within the
culture. In number of well-controlled experiments we attempted to
induce trisomy in hNPCs using various acute or chronic cell
culture stressors including, sub-optimal cryopreservation and
passaging techniques, however, we were never able observe a
trisomy in those hNPCs (data not shown).
Trisomy hNPCs survive better in rat brain xenografts but
do not form tumors
In order to test whether a trisomy line may induce tumor
formation in vivo, the M031
+7, and +19 hNPCs were transplanted
into the striatum of adult rats in one hemisphere along with
M031
dip controls in the contralateral hemisphere. The U87 glioma
line (similar to some brain tumor stem cell lines exhibiting typical
neoplastic karyotype: Figure S4) was used as a positive control for
malignant tumor formation. After 6 weeks, the animals were
sacrificed and the numbers of surviving cells were then counted in
the striatum using the human specific nuclear marker (hNu). The
M031
dip cells had a typical transplant survival as we have observed
in previous studies (Figure 5A) [18,30,31]. The overall survival of
hNPCs was significantly increased in the trisomy 7 and 19 groups
when compared to diploid controls (Figure 5B and D). However,
there was no sign of perivascular cuffing or other cellular
overgrowth suggestive of tumor formation (Figure 5B). We utilized
the U87 cells, a highly aggressive astrocytoma line, as controls
showing that tumors can form in the rat model. In stark contrast to
the hNPC lines, U87 cells formed tumors of a progressively
enlarging, well-defined cell mass consisting of highly packed
undifferentiated small rounded single mitotic elements (Figure 5C).
Discussion
In the present study, we illustrate that while many hNPC lines
derived from different fetal sources are karyotypically normal,
Figure 1. Trisomy of chromosome 7 and 19 in M031 CTX hNPC line. (A, B) Compared to the wild type controls (
dip), (C, D) sub-cultures of
M031 CTX line display a complete trisomy of chromosome 7 (
+7), (E, F) and a trisomy of chromsome19 (
+19) after fourteen to thirty-eight passages.
(A, C, E) Twenty metaphase cells were examined by G-banding, (B, D, F) and 200 interphase nuclei were evaluated by fluorescence in-situ
hybridization (FISH). Results are representative of at least one of three independent biological samples with similar results.
doi:10.1371/journal.pone.0007630.g001
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one line displayed trisomy 19. These trisomies appear to occur
stochastically between different hNPC lines. However, no other
trisomies were detected in other lines despite extensive karyotyp-
ing. Therefore, provided culture conditions and karyotyping is
carefully monitored, these cells still provide a safe source of neural
Figure 2. Growth and proliferative advantage of M031
+7 and M031
+19 over M031
dip CTX hNPCs. (A–D) Immunocytochemistry for Ki67
protein, a cell-cycle associated proliferation marker, shows significantly more Ki67 positive cells in both M031
+7(21%) and M031
+19 (22%) compared to
the M031
dip line (10%). (E–H) Cell death analysis using TUNEL staining shows that compared to the M031
dip control (31%), there was a significant
decline in the number TUNEL positive cells in the M031
+7 (13%) and M031
+19 (22%) hNPCs. (I–L) Immunocytochemistry for the catalytic subunit of
telomerase (hTERT) exhibits significant increase in the number of hTERT positive cells in M031
+7 (49%) and M031
+19 (48%), when compared to
M031
dip controls (,31%). p value: ** ,0.01 and * ,0.05. The magnified images for (B) Ki67, (E) TUNEL, and (J) hTERT immunostaining are shown in
insets. Images are representative of one of three independent experiments with similar results. The data in the graphs are averaged over three
independent experiments with mean and SEM values.
doi:10.1371/journal.pone.0007630.g002
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+7 and M031
+19
lines overexpress EGFR family proteins resulting in increased activation of phosphorylated EGFR (Tyr992). (B) Desnitometry quantification of scanned
bands using ImageJ 1.17 software displays ,2 to 3-fold increase in EGFR protein levels and 3 to 4-fold increase in Her-2 protein levels in trisomy
hNPCs. p value: ** ,0.01,* ,0.05, and ns=not significant. Immunoblotting images are representative of one of three independent experiments with
similar results. The data in the graph is averaged over three independent experiments with mean and SEM values.
doi:10.1371/journal.pone.0007630.g003
Figure 4. EGF independence in M031
+7 hNPCs and EGF deprivation to a normal G016 CTX line leads to trisomy of chromosome 7.
(A, B) Following 12-day EGF withdrawal, M031
+7 line manifests a 2-fold increase in EGF-independent growth evident from an increase in Ki67 positive
cells and decrease in TUNEL positive cells by immunocytochemistry. p value:,* ,0.05, and ns=not significant. Images in A are representative of one
of three independent experiments with similar results. The graph in B is averaged over three independent experiments with mean and SEM values.
(C) FISH analysis for control centromeric chromosome enumerating probes (CEP) X (green) and CEP 7 (red) shows that EGF depletion for four weeks
from the hNPC expansion media results in stress-associated trisomy of chromosome 7 in G016 hNPCs, as indicated by the three red spots in the
nucleus. Normal diploid cells display two red spots. 7% (14/200)61% of the cell population had trisomy 7 after nuclei were counted. Under similar
conditions the G010 CTX line never displayed any trisomy 7. This experiment was repeated two times, data was averaged over those experiments and
represented by mean and SEM values.
doi:10.1371/journal.pone.0007630.g004
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also demonstrated that the stress of EGF withdrawal can lead to
trisomy 7 cells emerging from karyotypically normal diploid
cultures, suggesting that maintaining optimal culture conditions
may be crucial for long term growth of the cells.
The occurrence of cytogenetic aberrations is common in
dividing cells, but most are not viable. However, survival of cells
with specific chromosome changes, and their ability to replace the
normal diploid cells in culture, implies that these changes impart a
growth advantage to those cells in which they arise. These cells are
termed ‘‘culture-adapted’’ since they have been selected for
improved growth in culture [2,32]. Cultured hESCs have been
reported to acquire genetic and epigenetic changes that make
them vulnerable to transformation and neoplastic transformation
even without harboring any chromosomal abnormalities [33].
Selection for multiple recurrent cytogenetic changes may lead to
uncontrolled cell division and morphological alterations, thus
converting a normal cell to a cancer cell (i.e. transformation).
Therefore, according to the multi hit model of cancer early
cytogenetic changes like trisomy 7 or 19 that lead to a growth
advantage may be the ‘‘first hit’’ required for progression to
transformation, ultimately resulting in tissue-specific tumors. For
example, trisomies 12 and 17 are characteristic findings in human
germ cell tumors, while trisomies 8 and 11 are common changes in
mouse tumors [2,6,7,34]. Interestingly, trisomy 7 is a characteristic
finding in glioblastoma [35,36] and trisomy 19 is characteristic of
ependymoma [37]. Thus, just as hESC trisomies mirror changes in
germ cell tumors [34,38], trisomies of 7 and 19 may mirror
chromosome changes seen in tumors of neural lineage. Future
experiments in our laboratory will test this hypothesis.
The trisomy hNPCs displayed faster population doubling in
culture than the diploid hNPCs, partly due to increased cell
proliferation (Fig. 2A–D) and inhibition of cell death (Fig. 2E–H).
Human telomerase catalytic subunit (hTERT) expression is crucial
for induction of senescence-associated genes and eventual
immortalization. Even though the trisomy hNPCs display higher
telomerase expression and extended growth in culture, they are
not immortalized as they enter a senescence phase between 50 and
70 weeks. It is known that senescence can be initiated by the
shortening of telomeres (replicative senescence) or by other
endogenous and exogenous acute and chronic stress signals in a
process termed as STASIS (STress or Aberrant Signaling Induced
Senescence) [39]. Growth inhibitory genes can be activated in cell
culture and in vivo due to STASIS or culture shock. STASIS works
through a different mechanism than telomere-based replicative
senescence. While cells undergoing replicative senescence can be
immortalized by expression of hTERT to maintain telomere
homeostasis, this does not occur in cells undergoing growth arrest
due to STASIS [39].
Interestingly, we observed an increase in EGFR expression and
activation (Tyr992 phosphorylation) in the trisomy 7 and 19
hNPCs. The SH2 domain of PLCc binds at phospho-Tyr992,
resulting in activation of PLCc-mediated downstream signaling
[40]. The presence of EGFR gene on chromosome 7 may
reconcile the selective proliferative advantage of the hNPC
+7 cells.
Additonally, important genes that regulate cell cycle, proliferation
Figure 5. Rat brain transplants of M031
+7 and M031
+19 hNPCs show improved survival, however, do not induce tumorigenesis. (A–
C) Immunohistochemical stain for human nuclear antigen (hNu) of M031
dip hNPCs, transplanted into the striatum of unlesioned rats in one
hemisphere along with (B) M031
+7 and (C) U87 glioma cells in the corresponding hemisphere. M031
+7 (and M031
+19; not shown here) hNPCs showed
no signs of invasiveness as compared to the positive control U87 glioma cells. (D) The relative proportions of surviving hNu positive cells 6-weeks
post-transplantation were noted by visual observation and scored. The overall survival of M031
+7 and M031
+19 compared to M031
dip control
significantly increased. p value is **=0.007, *=0.01.
doi:10.1371/journal.pone.0007630.g005
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transcription factor), mitogen-activated protein kinase kinase 2
(MAP2K2), Janus Kinase 3 (JAK3, and transforming growth
factor-beta 1 (TGFb1) are located on chromosome 19 [41]. It is
possible that some of these critical regulators of cell proliferation
up-regulated in the trisomy 19 cell lines play an important role in
paracrine/autocrine signaling resulting in EGFR overexpression
and autoactivation.
In the postnatal subventricular zone (SVZ) neural stem cells
(NSCs) give rise to transit-amplifying precursors (TAPs) expressing
high levels of EGFR that in turn generate neuroblasts. Recently, it
has been shown that distal-less (DLX)2 homeobox transcription
factor and EGFR signaling interacts at multiple levels to
coordinate neurogenesis and proliferation in the postnatal SVZ
by promoting the lineage transition from NSCs to TAPs [42].
Other studies have also elucidated the importance of EGFR
expression and signaling during regulation of neurogenesis
[43–45]. Since both the trisomy hNPC lines overexpress EGFR
and have increased EGFR activation in culture, it is likely that this
may lead to increased generation of neuroblasts and subsequent
increase in neuron production upon differentiation when com-
pared to the diploid line. We have also shown that hNPC
neurospheres grown in high concentrations of EGF grow faster
and have greater neurogenesis [46].
A major role of EGFR in the malignant transformation is
emphasized by loss of EGF sensitivity and acquisition of an extra
chromosome 7p harboring the EGFR gene, as a consequence of
EGF deprivation [28]. There is recent indication that neural stem
cells within subventricular zone (SVZ) may give rise to tumors like
GBM’s and suggestions that telencephalic proliferative regions of
the mammalian brain, including the embryonic cerebral cortex
and postnatal SVZ may contain a population of aneuploid cells
[20,21,47,48]. Approximately, 50–75% of glioblastoma’s (GBM’s)
exhibit EGFR gene amplification and trisomy/polysomy of
chromosome 7 in addition to other chromosomal aberrations
[35,36]. Additionally, a newly recognized subset of trisomy 19
ependymal tumors that are supratentorial WHO grade III tumors
of the young has been reported [37].
Cancer arises from accumulations of genetic changes in
pathways involved in cell cycle, cell proliferation, apoptosis,
angiogenesis and interaction with extracellular matrix. This
usually leads to an abnormal karyotype as shown for some BTSCs
(Figure S4). The trisomy 7 or 19 cultures described here did not
display a cancer phenotype, nor did they produce malignant
tumors upon transplantation into immunosuppressed rats. How-
ever, we cannot rule out that a trisomy may confer a vulnerability
of the cells to subsequent malignant changes under appropriate
stress conditions. Given that acquisition of a trisomy is the most
frequent karyotypic change found in stem cells, it is possible that
these cells are susceptible to errors in proper chromatid separation
during mitosis. For example, the G2 decatenation check point
responsible for delaying entry into mitosis if the chromosomes
have not been sufficiently untangled or decatenated has been
reported to be highly inefficient in mouse ESCs [49]. Defects at
the mitotic spindle checkpoint that ensures proper sister chromatid
alignment before their separation has also been reported to cause
aneuploidy if segregation occurs while chromatids are attached to
a single spindle [50]. Thus the emergence of clonal populations of
karyotypically abnormal stem cells may involve mitotic errors
followed by selection for those changes that are most adaptive for
those cells in their culture environment. Additionally, hESCs with
trisomies demonstrate enhanced neurotrophin signaling, which
may provide a selective advantage under suboptimal culture
conditions [51]. This suggests that recurrent aneuploidies in
cultured cells may be driven by stresses in the immediate cell
environment (e.g. media composition, oxygen tension, subculture
methods, etc), similar to our observation in this report that stress of
EGF deprivation may be a trigger for trisomy 7 (Figure 4C).
Alternatively, EGF withdrawal may be selecting for rare cell(s)
with trisomy 7 that subsequently due to a selective advantage
dominate the culture population. More studies are required to
define exactly what causes trisomies in stem cell culture models.
There are different methods being developed for isolating and
expanding hNPC cultures by academic labs and commercial
companies [8,9,52,53]. StemCells Inc. performs direct isolation of
fetal brain tissue-derived hNPCs based on fluorescence-activated
cell sorting (FACS) of CD133(+) cells (cell surface marker),
subsequent expansion as neurospheres and transplantation of
early passage cultures in a clinical trial for Batten’s disease
[52–54]. This company has not reported trisomies within their
culture system, although they do not maintain the cells for more
than 10 weeks prior to transplantation. Other groups grow fetal
and hES-derived NPCs in adherent monolayer culture in EGF
and FGF-2 and has shown that they maintain a diploid karyotype
[55,56]. It is unclear whether our method of maintaining cells in
EGF and LIF combined with neurosphere chopping rather than
mechanical or enzymatic dissociation used in other methods
results in a differential rates of trisomy occurrence, or whether
trisomies observed in other systems have not been reported. Other
protocols are also being developed for transitioning hES-derived
NPCs into clinical trials [56–59]. In particular, Geron Corp. has
recently received FDA clearance for transplanting hES-derived
oligodendrocyte neural progenitors into acute spinal cord injury
patients [58–60]. Again, it is not clear if these methods of hNPC
expansion result in aneuploidies in some cultures, however, careful
monitoring for the development of trisomies will be required.
In conclusion, our results suggest that microenvironmental cues
are powerful factors in the selection of specific hNPC aneuploidies.
We detected frequent chromosomal changes in 5 hNPC cell lines,
with trisomy of chromosome 7 being the most common. Even
though the M031 trisomy hNPCs have high telomerase levels
combined with increased proliferation rates and lowered apopto-
sis, the cells eventually undergo replicative senescence in vitro just
as other hNPCs [61]. They do not form neoplastic overgrowths
following transplantation into the adult rat brain, although, they
appear to have improved survival rates compared to normal
diploid lines. Furthermore, our previous studies have shown that
M031 hNPCs can survive transplantation without displaying any
signs of tumor formation into models of photoreceptor degener-
ation [61], amyotrophic lateral sclerosis [30] and Parkinson’s
disease [31], supporting the general application and safety of these
cells, although we are not entirely certain if some of the hNPC
population at the time of transplantation carried chromosome 7 or
19 trisomy. However, a recent report also shows the dangers of
grafting an inordinate number of cells and the need for careful
monitoring of hNPCs before proceeding to clinical trials [62].
Therefore, regular monitoring of the karyotype of hNPCs (fetal or
hESC-derived) will be essential before these cells are used in future
clinical trials as trisomy of chromosomes 7 and 19 lessen the
reproducibility and reliability of therapeutic outcomes and pose a
higher risk of potential tumor formation.
Materials and Methods
Ethics statement
Human fetal brain tissue (between 10 and 15 weeks of post-
conception) was obtained from the Birth Defects Laboratory at the
University of Washington. The method of collection conformed to
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the collection of such tissues and set out by the University of
Washington and the University of Wisconsin, Madison. All the
animal care treatment protocols and procedures in the present
study were carried out in accordance with the guidelines approved
by the University of Wisconsin-Madison Research Animals
Resources Center and National Institutes of Health standards of
animal care. Institutional Review board approval was obtained for
all of these studies.
Human neural progenitor cell culture
Briefly, hNPCs were prepared from freshly dissected fetal brain
cortical tissue was dissociated in 0.1% trypsin and seeded into T75
flasks at a density of 200,000 cells per ml of maintenance medium
[Dulbecco’s modified Eagle medium (DMEM)/Ham’s F12 (7:3)
containing penicillin/streptomycin/amphotericin B (PSA, 1% v/v)]
supplemented with B27 (2% v/v; Invitrogen), EGF (20 ng/ml;
Sigma-Aldrich), and fibroblast growth factor-2 (FGF-2; 20 ng/ml;
R&D Systems) with heparin (5 mg/ml; Sigma). Neurosphere
colonies rapidly formed and were passaged every 7–14 days by
sectioning neurospheres into 200 mm using an automated tissue
chopper as described previously [11,23]. At 2 weeks after the first
passage, the cells were switched to maintenance medium containing
N2 supplement (1%; Invitrogen) and 20 ng/ml EGF. After 10
weeks, 10 ng/ml LIF (Chemicon) was added to enhance expansion
rates. At this stage, the cultures have generally reached a stable
phase of growth where they produce a mixture of neurons and
astrocytes upon differentiation as described in detail previously
[19,23]. All cultures were maintained at 37uC in 95% O2/5% CO2.
G-banding and FISH
Giemsa (G-banding) stain and FISH using centromeric
chromosome enumeration probes (CEP) for chromosomes 7, 3,
and X and sub-telomeric probes for chromosome region 19p and
19q were performed on log-phase growth hNPCs according to
previously published methods [5].
Neurosphere growth measurements




were placed in a 96-well plate and were measured via Integrated
Morphometry Analysis using Metamorph software (Molecular
Devices, Dowington, PA). Sphere volume was calculated on day 0
and every second day up to 14 days after plating. Half of the
medium was exchanged every second day. Results are plotted as
sphere volume.
Immunocytochemistry and TUNEL assay
At the appropriate time points in culture, plated cells were fixed
in paraformaldehyde (PFA, 4% vol/vol) and rinsed in phosphate-
buffered saline (PBS). Fixed cultures were blocked in 3% (vol/vol)
goat serum with 0.3% (vol/vol) Triton X-100 and incubated with
primary antibodies to Ki67 (polyclonal, 1:1000,) to label
proliferating cells, and b-tubulin-III (monoclonal IgG2b, 1:500;
Sigma) and GFAP (polyclonal, 1:1000; DAKO) to label undiffer-
entiated neural progenitors or differentiating neurons and
astrocytes, respectively. After incubation with the primary
antibodies, cultures were rinsed in PBS and incubated in either
Cy3 or fluorescein-conjugated goat anti-rabbit antibodies. Nuclei
were counterstained with Hoechst 33258 (0.5 mg/ml; Sigma) and
mounted on glass slides using GelTol
TM Aqueous Mounting
Medium (Immunotech). Visualization of hNPCs was performed at
20X magnification (Nikon) and quantification of positive cells was
completed using Metamorph Offline software (Universal Imaging
Corporation). For TUNEL assay, dead cells were detected through
a TdT-mediated dUTP Nick End Labeling (TUNEL) assay and
Ki67 staining was later performed. The DeadEnd
TM Fluorometric
TUNEL System (Promega) kit was used and the manufacturer’s
instructions were followed. Following completion of TUNEL
assay, cells stained using standard immunocytochemical protocols
with rabbit anti-Ki67 (1:750) overnight at 4uC.
Differentiation studies
Dissociated neurospheres plated onto glass coverslips precoated
with poly-ornithine (100 mg/ml) and laminin (10 mg/ml) in wells
prefilled with standard plating medium (DMEM/HAMS-F12
supplemented with B27, 2% vol/vol). These conditions allowed for
rapid neurosphere adhesion and differentiation under serum-free
conditions. All differentiating NPC cultures were maintained in
humidified incubators at 37uC (5% CO2 in air). Half of the culture
medium was replenished every 3 days.
RNA extraction for Affymetrix GeneChips
Total RNA from diploid and
+7 hNPCs that were at
approximately passage 20 was extracted using Trizol reagent.
Total RNA was further extracted using a chloroform/isopropanol
separation method. Finally, RNA was ethanol precipitated and
allowed to briefly dry before elution in 33 ml of RNase-free water.
The quality of the RNA of each sample was assessed by
spectrophotometer readings (optical density 260/280=2.0 for
each RNA).
Affymetrix GeneChip sample preparation and analysis
cDNA synthesis was performed for hNPCs using the One-Cycle
cDNA Synthesis Kit (Affymetrix, Santa Clara, CA). In brief,
double-stranded cDNA was synthesized using a Oligo(dT)24
primer at the 39 end for priming the firststrand cDNA synthesis by
Superscript II reverse transcriptase and the T7 RNA polymerase
promoter sequence at the 59 end. cDNA was purified using the
cDNA Sample Cleanup Module provided with the One-Cycle
cDNA Synthesis Kit and resuspended in 14 ml Elution Buffer.
Biotin-labeled cRNA was synthesized using the IVT Labeling Kit
(Affymetrix, Santa Clara, CA) and incubated at 37uC for 16 hours.
cRNA was purified with the cRNA Sample Clean-up Module
provided with the IVT Labeling Kit and eluted in 21 ml.
Spectrophotometric analysis was used to determine the cRNA
yield as well as the quality of cRNA (optical density 260/280=2.0
for each cRNA). An adjusted cRNA yield was calculated to reflect
any carryover of unlabeled total RNA. cRNA was fragmented
using the 5X Fragmentation Buffer (Affymetrix, Santa Clara, CA)
provided, at a final concentration of 0.5 mg/ml, in order to break
down full-length cRNA to 35 to 200 base fragments. Fragmented
biotin-labeled cRNA samples were then hybridized to the U133
Plus 2.0 Array at 45uC for 16 hours. Hybridized arrays were
washed and double-stained with streptavidin-phycoerthrin using
the Fluidics Station 400 (Affymetrix, Santa Clara, CA) as defined
by the manufacturer’s protocol. RNA extractions were performed
on the
dip and
+7 hNPC lines and processed separately on
GeneChips. Stained U133 Plus 2.0 arrays were scanned at 3 mm
resolution using the Affymetrix GeneChip Scanner 3000 at the
Gene Expression Center (University of Iowa, Iowa City, IA).
GeneChip Operating Software v1.2 (GCOS) was used to analyze
the relative abundance of each gene derived from the average
difference of intensities. Log transformed data was then analyzed
further using the GeneSifter software. Gene expression ratios were
generated using M031
dip control cells from an RNA extraction as
the baseline for comparison with M031
+7 cells generated from an
RNA extraction. Statistical analysis of GeneChip data was
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conducted for each data set with only genes with a p value
,0.05 being considered in the statistical analysis. The Affymetrix
microarray dataset for the samples are deposited with Gene
Expression Omnibus (GEO) with accession numbers, GSE18349,
GSM458064, and GSM458065.
Cell transplantation
hNPC neurospheres were prepared for transplantation: U87
glioma control cell line, M031 control neurospheres (
dip; passage
27), trisomy 7 (
+7; passage 25),and trisomy 19 (
+19; passage 26) were
collected and the media was removed. Neurospheres were
dissociated to single cells by incubation with Accutase for 10 min
at 37uC, trypsin inhibitor for 5 min at 37uC, and DNase for 10 min
at 37uC, followed by manual dissociation into single cell
suspensions. Cells were counted and resuspended at a density of
100,000 cells/ml in a 1:1 mix of Liebowitz (L-15) media and 0.6%
glucose in sterile PBS supplemented with 2% B27. Cell suspensions
were maintained on ice during transplantation procedures. Rats
were randomly assigned to a cell treatment group and injected
unilaterally with 200,000 cells: 6 rats received
+19; 6 rats received
+7;
and 3 rats received U87 cells. All 15 rats received an additional
injection of 200,000
dip cells into the opposite striatum to serve as a
control. The striatal injection site was calculated from bregma:
AP60.5; ML63.3. A 30 g needle attached to a 10 ml Hamilton
syringe was lowered to DV -5 and left in place for 3 min. An
infusion pump delivered the cells at a rate of 1 ml/min. The needle
was left in place for an additional 5 min before being slowly
removed. All rats received cyclosporine injections (i.p. 10 mg/kg) 1
day before and every day following transplantation. Two to four
weeks following transplantation, rats were perfused with chilled
0.9% saline followed by 4% PFA. Brains were post-fixed for 24 h in
4% PFA followed by 30% sucrose. Brains were then sectioned at
40 mm on a sliding microtome (Leica).
Immunohistochemistry
Following fixation of brains in 30% sucrose for 48 hours, 40 mm
coronal sections were cut on a freezing microtome. Sections were
washed in Tris-HCl, incubated in 2N HCl for 30 minutes, and
quenched by submerging sections in phosphate-buffered saline
(PBS) with 10% hydrogen peroxide in 10% methanol for 30
minutes. To stain for human nuclei (hNu), human nestin and
GFAP in grafts, all sections were blocked for one hour in 10%
normal horse serum (NHS) at RT followed by a 24 h incubation at
4uC with one or combination of primary antibodies - mouse anti-
human nuclei (1:200, Chemicon) or mouse anti-hNestin (1:200
need manufacturer) and anti-GFAP in Tris-HCl/0.1% Triton X-
100 and BSA. Sections were then incubated in a biotinylated
secondary antibody (horse anti-mouse, 1:200, Vector) followed by
Vectastain ABC (Vector). Sections were processed with 3,3-
diaminobenzidine (DAB, Sigma) as a chromagen between 3 to
7 min and mounted on glass microscope slides. An ethanol
dehydration series was performed (70%, 95%, 100%) and was
cleared with CitriSolv. Slides were ultimately coverslipped using
GelTol
TM Aqueous Mounting Medium (Immunotech). hNu
positive cells were quantified using Metamorph Offline software
(Universal Imaging Corporation). The number of human nuclei
was determined in every eleventh section throughout the striatum.
The total number of human nuclei in the graft was determined by
multiplying these counts by the interval.
Immunoblotting
Cultures were washed twice with PBS and lysed in ice-cold lysis
buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% Nonidet
P-40, 1 mM PMSF, 1 mM NaF, 1 mM DTT and 4 mg/ml
complete protease inhibitor cocktail]. Protein concentration was
determined in cell lysates using the Bio-Rad protein assay kit.
Aliquots of protein were mixed with SDS sample buffer and
Western blot analysis performed using standard protocols. Ten or
40 mg protein extracts were denatured in Laemmli sample buffer
followed by 5 minutes of boiling and then resolved on a 10% or
8% Tris-glycine gel (Novex, San Diego, CA). After electrophoresis
(120 V for 2 hours), the proteins were transferred in 1x transfer
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, and 20%
methanol [,pH 8.4]) to a nitrocellulose membrane (Hybond-
ECL; GE Healthcare; Piscataway, NJ), with constant current of
100 mA for 2 or 3 hours. The membranes were then blocked in
5% nonfat dry milk TBS solution for 1 hour at room temperature.
The blots were incubated overnight at 4uC with one of the
following antibodies: AB19012 (Chemicon International, Teme-
cula, CA), M61403 (Biodesing International, Saco, ME), 1310-01
(Southern Biotechnology, Birmingham, AL), MAB13405 (Chemi-
con International), MAB3328 (Chemicon International), or
AB19078 (Chemicon International). The membranes were washed
three times with TBS solution including Tween-20 (TBS-T)
incubated with horseradish peroxidase–linked donkey anti-mouse,
donkey anti-goat or donkey anti-rabbit antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) for 2 hours at room temperature
and then washed four times in TBS-T. Detection of the
immunoreactive bands was performed with the ECL chemilumi-
nescene detection kit (GE Healthcare). The bands were scanned
and quantitated by densitometry (ImageJ 1.17 software; National
Institutes of Health [NIH], Bethesda, MD; available by ftp at
zippy.nimh.nih.gov/ or at http://rsb.info.nih.gov/nih-image;
developed by Wayne Rasband, National Institutes of Health,
Bethesda, MD).
Statistical analysis
Prizm software (GraphPad software, La Jolla, CA) was used for
all statistical analyses. All counting data from immunocyto/
histochemical analyses and cell survival in the animals were
expressed as mean values 6 SEM and analyzed by two-tailed t-test
or two-way ANOVA with Bonferonni post hoc test. Differences
were considered significant when p,0.05.
Supporting Information




dip CTX hNPCs. (A) Morphological comparison of trisomy
hNPCs demonstrates significantly greater size in comparison with
the wild-type diploid hNPCs. Images are representative of one of
three independent experiments with similar results. (B) Volumetric
measurements of single neurospheres over two weeks exhibit that
M031
+7 and M031
+19 had ,100% and 60% greater increase in
neurosphere volume, respectively, than the M031
dip line. p value:
** ,0.01 and * ,0.05. The data in the graph is represented by
average of three independent experiments with mean and SEM
values.
Found at: doi:10.1371/journal.pone.0007630.s001 (6.89 MB TIF)
Figure S2 Increased survival of M031
+7 and M031
+19 hNPCs.
Upon differentiation for 7 to 14 days the M031
+7 and MO31
+19
lines showed significantly greater survival than the M031
dip
controls, as determined by the percent of Ki67 and TUNEL
positive cells. p value: ** ,0.01, * ,0.05, and ns=not significant.
Images are representative of one of three independent experiments
with similar results. The data in the graphs are averaged over three
independent experiments with mean and SEM values.
Found at: doi:10.1371/journal.pone.0007630.s002 (9.88 MB TIF)
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+7 and M031
+19
hNPCs. Following one, seven, and fourteen days of differentiation,
bIII-tubulin (green) and GFAP (red) immunofluorescence estab-
lishes that the M031
+7 and MO31
+19 lines generated significantly
more bIII-tubulin positive neurons and proportionately less GFAP
positive astrocytes, compared to the M031
dip controls. p value: ***
,0.001, ** ,0.01, * ,0.05, and ns=not significant. Images are
representative of one of three independent experiments with
similar results. The data in the graphs are averaged over three
independent experiments with mean and SEM values.
Found at: doi:10.1371/journal.pone.0007630.s003 (9.74 MB TIF)
Figure S4 Abnormal karyotype of brain tumor stem cell (BTSC)
lines. FISH analysis for chromosome 7 (green) and chromosome 3
(red) using respective chromosome enumerating probes reveals the
distinctly abnormal heterogeneous karyotype of three BTSC lines.
Nuclei were counterstained with Hoechst dye (blue). FISH staining
and analyses were performed in triplicate.
Found at: doi:10.1371/journal.pone.0007630.s004 (6.55 MB TIF)
Table S1 Selective advantage of the trisomy hNPCs in culture.
Once detected in a sub-culture, the frequency of hNPC
+7 and
+19
occurring cells increased over subsequent passages and predom-
inated within ten to fifteen weeks of first detection. Tests that were
not performed are represented by ‘‘NP’’ in the relevant column.
Results are representative of at least one of three independent
biological samples with similar results.
Found at: doi:10.1371/journal.pone.0007630.s005 (0.07 MB
DOC)
Table S2 EGFR mRNA is upregulated in hNPC
+7 cells.
Affymetrix GeneChip Microarray comparison of M031
dip and
M031
+7 lines revealed that 105 genes were up-regulated and 16
were down-regulated more than 1.5 fold on chromosome 7.
Interestingly, expression of the EGFR gene increased 1.7-fold.
Gene expression ratios were generated using M031
dip control cells
from an RNA extraction as the baseline for comparison with
M031
+7 cells generated from an RNA extraction.
Found at: doi:10.1371/journal.pone.0007630.s006 (0.25 MB
DOC)
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